Germany’s Merck KGaA to purchase SpringWorks Therapeutics
Andrew Joseph , 2025-04-28 07:17:00 Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. After months of discussion, Germany’s Merck KGaA said Monday it would buy SpringWorks Therapeutics for $47 a share in cash, a deal with an equity value of nearly $4 billion. The…